<DOC>
	<DOCNO>NCT02637856</DOCNO>
	<brief_summary>This study evaluate efficacy safety ocrelizumab participant RRMS suboptimal response adequate course DMT . Participants receive ocrelizumab initial dose two 300-milligrams ( mg ) intravenous ( IV ) infusion ( 600 mg total ) separate 14 day follow one 600-mg IV infusion maximum 4 dos ( 96 week ) . Anticipated time study treatment 96 week .</brief_summary>
	<brief_title>A Study Ocrelizumab Participants With Relapsing Remitting Multiple Sclerosis ( RRMS ) Who Have Had Suboptimal Response Adequate Course Disease-Modifying Treatment ( DMT )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Diagnosis multiple sclerosis ( specifically RRMS ) , accordance revise 2010 McDonald criterion Disease duration first symptom less equal ( &lt; /= ) 12 year Treated adequate course treatment three prior DMT regimens great equal ( &gt; /= ) 6 month , discontinuation recent adequately used DMT due suboptimal response Suboptimal response participant his/her last adequately use DMT &gt; /=6 month ( define one follow qualify event despite stable dose DMT least 6 month : one clinically report relapse , one T1 Gdenhanced lesion , two new enlarge T2 lesion MRI ) ; qualify event must occur last adequately use DMT . In participant receive stable dos approve DMT year , event must occur within last 12 month treatment DMT date screen History primary progressive multiple sclerosis ( PPMS ) , progressive relapse multiple sclerosis ( PRMS ) , secondary progressive multiple sclerosis ( SPMS ) Contraindications MRI Known presence neurological disorder may mimic multiple sclerosis Pregnancy lactation Requirement chronic treatment systemic corticosteroid immunosuppressant course study History currently active primary secondary immunodeficiency Lack peripheral venous access History severe allergic anaphylactic reaction humanize murine monoclonal antibody Active infection , history know presence recurrent chronic infection human immunodeficiency virus ( HIV ) , syphilis , tuberculosis History progressive multifocal leukoencephalopathy Contraindications intolerance oral IV corticosteroid Previous treatment fingolimod ( Gilenya速 ) dimethyl fumarate ( Tecfidera速 ) participant whose lymphocyte count lower limit normal ( LLN ) Treatment alemtuzumab ( Lemtrada速 ) Previous treatment systemic cyclophosphamide , azathioprine , mycophenolate mofetil , cyclosporine , methotrexate Previous treatment natalizumab within 12 month prior screen unless failure due confirm , persistent antidrug antibody ( ADAs ) . Participants previously treat natalizumab eligible study duration treatment natalizumab less ( &lt; ) 1 year natalizumab use 12 month prior screen . AntiJohn Cunningham virus ( JCV ) antibody status ( positive negative ) titer ( assess within year screen ) must document prior enrollment Treatment dalfampridine ( Ampyra速 ) unless stable dose &gt; /=30 day prior screen Treatment Bcell target therapy ( e.g. , rituximab , ocrelizumab , atacicept , belimumab , ofatumumab ) Treatment drug experimental ( Exception : treatment experimental drug subsequently approve participant 's country allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>